HA Filler Grades Explained: Monophasic vs. Biphasic and How to Choose

Why Does HA Concentration Tell You Almost Nothing About Clinical Performance?

The number printed on the box — 18 mg/mL, 20 mg/mL, 24 mg/mL — describes the gross weight of hyaluronic acid dissolved in the syringe. It does not describe how the HA chains are structured, how long the product will resist enzymatic breakdown in tissue, how soft or rigid the gel feels, or which anatomical plane it is engineered to support.

A dermal filler’s in-vivo behaviour is governed by three primary physicochemical parameters:

1. Cross-linking degree (Degree of Modification / DoM): How densely the HA chains are covalently bound.
2. Elastic modulus (G-prime / G’): How effectively the gel resists mechanical compression and projects overlying tissue.
3. Cohesivity: How tightly the gel particles hold together as a single bolus rather than dispersing into surrounding tissue planes.

Understanding these rheological parameters allows clinic directors and procurement teams to match product selection to clinical indication — rather than relying on commercial marketing labels like “Deep”, “Volume”, or “Sub-Q” that differ widely across manufacturers.

---

How Does BDDE Cross-Linking Chemistry Create Long-Lasting Hydrogels?

Natural hyaluronic acid is highly water-soluble and is degraded by endogenous hyaluronidase enzymes within 24 to 48 hours. To create an injectable implant capable of persisting for 6 to 18 months, manufacturers cross-link the linear polysaccharide chains into a three-dimensional polymer network.

The Role of 1,4-Butanediol Diglycidyl Ether (BDDE)

The global gold standard cross-linker for aesthetic medical devices is BDDE (1,4-butanediol diglycidyl ether). Under controlled alkaline conditions, the epoxide rings of BDDE react with the hydroxyl groups of the HA polymer, forming stable, non-hydrolyzable ether bonds.

Two parameters determine cross-linking quality:

• Degree of Modification (DoM): Measures what percentage of HA disaccharide units are chemically bonded to BDDE. Commercial fillers typically range from 4% to 12% DoM. Higher DoM yields a stiffer, longer-lasting hydrogel; lower DoM yields a softer, more fluid gel.
• Residual Unreacted BDDE: Unreacted BDDE monomer must be rigorously removed via extensive dialysis and washing. Under EU MDR and ISO 10993 biocompatibility standards, residual BDDE must strictly measure < 2 ppm (parts per million), typically validated via high-performance liquid chromatography (HPLC) or GC-MS.

---

Monophasic vs. Biphasic Architecture: Which One Delivers Superior Lifting Power?

The terms monophasic and biphasic describe the physical microstructure of the hydrogel produced during cleanroom manufacturing.

Monophasic Fillers (Monolithic or Polydensified)

In monophasic manufacturing, cross-linking occurs across the entire polymer mass, which is then passed through sizing screens without separating phases.

• Monophasic Monolithic: The gel is cross-linked as a uniform block and sieved into smooth, cohesive cohesive masses.
• Monophasic Polydensified: The gel contains zones of varying cross-linking density, enhancing integration across fine superficial wrinkles.

Clinical Characteristics:

• Extremely smooth extrusion through 27G / 30G needles.
• Homogeneous, soft tissue integration without palpable edges.
• Ideal for dynamic facial zones (perioral, lips, fine superficial lines).

Biphasic Fillers (Particulate Suspension)

In biphasic manufacturing, a highly cross-linked HA gel is sieved into uniform, calibrated micro-particles. These particles are subsequently suspended in a fluid carrier consisting of non-crosslinked hyaluronic acid.

Clinical Characteristics:

• Superior vertical projection (high G-prime) per unit volume.
• Supports overlying muscle and skin when placed supraperiosteally (on bone).
• Requires higher extrusion force (typically 15–25 N) during injection.
• Ideal for deep structural volumisation (cheeks, chin, jawline, deep nasolabial folds).

---

Parametric Comparison: Dermal Filler Grades Across Indications

The table below outlines the target physical and rheological parameters required for each clinical indication:

Product Grade	Target Indication	Recommended G’ (Pa)	HA Concentration	Particle Sizing	Extrusion Force	Typical Needle / Cannula	Expected Duration
Fine / Soft	Periorbital, tear trough, fine superficial lines	50 – 150 Pa	18 – 20 mg/mL	< 150 µm	10 – 14 N	30G Needle / 27G Cannula	6 – 9 Months
Derm / Medium	Lips, moderate nasolabial folds, marionette lines	150 – 300 Pa	20 – 24 mg/mL	150 – 250 µm	12 – 18 N	27G Needle / 25G Cannula	9 – 12 Months
Deep / Volume	Malar augmentation, deep folds, temporal hollows	300 – 500 Pa	24 mg/mL	250 – 400 µm	15 – 22 N	25G / 27G Cannula	12 – 15 Months
Sub-Q / Structural	Chin projection, jawline definition, rhinoplasty	500 – 750+ Pa	24 – 26 mg/mL	400 – 600 µm	18 – 25 N	23G / 25G Cannula	15 – 18+ Months

---

What Is G-Prime and How Does It Dictate Product Selection by Anatomical Zone?

G-prime (G’), or the elastic storage modulus, is measured in Pascals (Pa) using an oscillatory shear rheometer. It represents the energy stored in the elastic structure of the gel during deformation. In clinical practice, G’ dictates how well the filler resists compression from facial expression, gravity, and muscle movement.

• Low G-prime (< 150 Pa): The gel behaves like a supple, moldable cushion. It integrates smoothly into the superficial dermis without creating lumps or the Tyndall effect.
• Medium G-prime (150–300 Pa): Provides balanced flexibility and volume retention. Perfect for lips and dynamic wrinkles where the tissue moves constantly.
• High G-prime (> 450 Pa): The gel acts as a structural prosthetic scaffold. It must be injected deep (supraperiosteal or deep subcutaneous) to lift heavy tissue envelopes without flattening.

---

How Do You Audit an HA Filler Technical Datasheet Before Issuing a Purchase Order?

When evaluating a new manufacturer or requesting product documentation, demand an official Product Specification Sheet & Batch Certificate of Analysis (CoA) verifying the following parameters:

1. Free vs. Cross-linked HA Ratio: Must match the intended clinical indication.
2. Residual BDDE Level: Must be certified < 2 ppm under validated GC-MS/HPLC testing.
3. Endotoxin Level: Must be strictly < 0.5 EU/mL (or < 0.2 EU/syringe under Ph. Eur. standards) to prevent delayed-onset inflammatory nodules.
4. Osmolality and pH: Must remain within physiological limits (280–320 mOsm/kg and pH 6.8–7.4) to minimize injection burning and edema.
5. Sterility Assurance Level (SAL): Must confirm terminal moist-heat steam sterilization achieving SAL 10⁻⁶.

A manufacturer unable to provide rheology curves and batch-specific endotoxin counts within 48 hours fails fundamental ISO 13485 traceability criteria.